Two Alleles of the Human Paraoxonase Gene Produce Different Amounts of mRNA
- 1 November 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 17 (11) , 2935-2939
- https://doi.org/10.1161/01.atv.17.11.2935
Abstract
In a recent study we demonstrated that a polymorphism of the human paraoxonase gene affecting position 54 was linked to variations in serum concentrations of the enzyme. L allele carriers (leucine at position 54) have significantly higher concentrations of paraoxonase than M allele carriers (methionine at position 54). In the present study we examined the hypothesis that differences in mRNA production could contribute to variations in serum concentrations. Relative concentrations of L and M type mRNA were analyzed in total RNA extracted from heterozygous liver samples. This was achieved by cDNA synthesis, polymerase chain reaction amplification of the cDNA fragment containing the 54 polymorphism and restriction analysis to identify radiolabeled end fragments of L and M alleles. An allele mixing experiment using total RNA from liver samples of LL and MM homozygotes demonstrated the sensitivity of the approach to changes in the relative concentrations of each type of RNA. In 8 of 10 heterozygous samples, an excess of L allele type mRNA was observed. Overall there was a significantly higher level of L type mRNA (L:M ratio of 2.51 +/- 1.41, n = 10, P < .01). These results support our hypothesis that increased concentrations of serum paraoxonase arise from greater production of L allele mRNA. In two samples, the L:M ratio was close to or below 1.0. This is consistent with the known spectrum of paraoxonase serum concentrations associated with the L and M alleles and suggests that factor(s) that preferentially modulate allele expression are usually, but not uniformly, associated with the L allele.Keywords
This publication has 20 references indexed in Scilit:
- A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease.Journal of Clinical Investigation, 1995
- Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.Journal of Clinical Investigation, 1995
- Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetesThe Lancet, 1995
- Lipoprotein oxidation in dyslipidemiaCurrent Opinion in Lipidology, 1995
- Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonaseAtherosclerosis, 1993
- Identification of a distinct human high‐density lipoprotein subspecies defined by a lipoprotein‐associated protein, K‐45European Journal of Biochemistry, 1993
- Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoproteinFEBS Letters, 1991
- Beyond CholesterolNew England Journal of Medicine, 1989
- Skeletal muscle characteristics of reindeer (Rangifer tarandus L.)Comparative Biochemistry and Physiology Part A: Physiology, 1985
- Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol depositionProceedings of the National Academy of Sciences, 1979